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Abstract  
Fibrate and statin combinational therapy is used to treat severe and refractory mixed 
hyperlipidemia. Hence lipid based SNEDDS were prepared using the concentration oil (2:1) 
and SCoS (1:1) which resulted in enhanced extent of absorption and relative bioavailability 
of 1.69 (fibrate)  and 1.64 (statin). An approximately 40% of drug was available for systemic 
circulation via lymphatic route of absorption. The results showed a significant difference 
between the marketed and the SNEDDS      
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Intoduction  
Oral route is the most commonly preferred route for drug delivery of wide variety of 
drugs. BCS Class II drugs suffer from poor water solubility and high lipophilicity resulting in 
fluctuations in drug plasma level, influence by food, rapid metabolism leading to failure of 
conventional drug delivery systems (1). These drug exhibit variable bioavailability and need 
improvement in the dissolution rate by different methods like lipid formulations, amorphous 
formulations like solid dispersion systems etc., for improving bioavailability(2). The choice 
of formulation is often of critical importance in establishing a successful product for oral 
administration of a BCS class II drug. Even though they contain potential pharmacodynamic 
activity they fail to reach market (3). The solubility of the drug could be increased in three 
ways: changing the chemical structure in the lead optimization phase; prodrug approach and 
the formulation approach. Lipid based drug delivery systems (LBDDS) are gaining 
importance these days due to their ability to deliver drug via lymphatic route restraining the 
hepatic metabolism. LBDDS (4) are a diverse group of formulations which are classified into 
4 types: Type I (oils without surfactants) , Type II(oils and water insoluble surfactants), Type 
III(oils, surfactants, co solvents), Type IV(water soluble surfactants and co-solvents). Of 
which Type III, popularly known as Self Nano Emulsifying Drug Delivery Systems 
(SNEDDS) are widely used because of its ease of formulation : simple self emulsification 
technique. SNEDDS (5) are defined as isotropic mixtures of natural or synthetic oils 
containing solid or liquid surfactants and one or more hydrophilic solvents. They form fine 
oil in water (o/w) emulsions on contact with GI fluids. The drug in SNEDDS remains in the 
solution form throughout its GI transit time whereby they circumvent the dissolution step. It 
involves digestion of the excipients and formation of different colloidal structures. The drug 
gets partitioned into these structures before it is absorbed. Thus they enhance the 
bioavailability of CLASS II drugs (6). SNEDDS improve the bioavailability by facilitating 
transcellular and paracellular absorption and inhibiting P-gp & CYP450 enzymes thereby 
decreasing intestinal efflux and drug biotransformation (7,8). The drug is absorbed through 
the lymphatics while chylomicrons are synthesized from the fatty components of the oil 
phase of the emulsion (9). 
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The main objective of the study is to formulate SNEDDS of the BCS Class II drugs, 
Fenofibrate and Rosuvastatin (10), as bioactives so that the drug can be delivered in the form 
of nanodroplets.  Fenofibrate is an antilipidemic agent that reduces both cholesterol and 
triglycerides in the blood by activating peroxisome proliferator activated receptor a (PPARa). 
Rosuvastatin is an antilipidemic agent that competitively inhibits hydroxymethyl glutaryl-
coenzyme A (HMG-CoA) reductase, which catalyses the conversion of HMG-CoA to 
mevalonic acid, the rate limiting step in cholesterol biosynthesis. Fenofibrate and 
Rosuvastatin combinational therapy is recomended for the treatment of severe or refractory 
mixed hyperlipidemia(11).  
The present marketed formulations face bioavailability problems, affected by first 
pass metabolism and pose toxicity due to intake of high doses (10). Hence suggesting 
SNEDDS for formulating Fenofibrate and Rosuvastatin improves bioavailability, bypass first 
pass metabolism and thereby decreases the dose of the drug and hence the toxicity. The thus 
formulated nanodroplets are characterized and evaluated for in-vitro, in-vivo performance and 
lymphatic absorption. Orally administered highly lipophilic compounds reach systemic 
circulation via intestinal lymphatic system (12). This alternative pathway from GIT has been 
shown to be significant contributor for overall bioavailability of a number of highly lipophilic 
drugs. Lymphatic transport of the drug provides many advantages such as avoidance of 
hepatic first pass metabolism and improved plasma profile of the drug.  
 
Materials and methods 
Materials  
Fenofibrate and Rosuvastatin drugs were obtained as a gift sample from Zim 
Laboratories, Nagpur; Capryol 90, Capmul MCM, Labrafac (LF), Isopropyl myristate (IPM), 
Lauroglycol (LG), Labrafac Lipophile WL 1349 (LL), Poloxamer 188, Cremophore EL, 
Cremophore RH 40, Gellusire 44/14 and Labrasol, Transcutol HP, Labrafil M 1944 CS were 
obtained as gift samples from Gattefosse Pvt. Ltd. (Mumbai, India). Neusilin was obtained 
from Fuji Chemical Industry Co. Ltd, Japan. Ethanol and Methanol (HPLC grade) were 
obtained from Merck chemicals India Pvt. Ltd., Mumbai. Avocadro oil was obtained from 
Swastik Eucalyptus Oil Co.  
 
Methods 
A Solubility studies (13) 
Solubility of Fenofibrate and Rosuvastatin was determined in various oils such as 
Capryol 90, Capmul MCM, LF, IPM, LG, LL, by shake flask method (14). An excess amount 
of drug was taken in 10 ml of the oil in vials, and mixed using vortex mixer. The vials were 
then kept at 25 ± 10C in an isothermal shaker for 72hrs to reach equilibrium. The equilibrated 
samples were then centrifuged at 3000rpm for 15min. The supernatant was filtered through a 
0.45μm membrane filter. The concentration of the drug (Table 1) was determined using UV 
Spectroscopy at 286.5nm and 243.5nm respectively.  
  (Compatibility studies were performed using FTIR 8400 S, Shimadzu. The IR 
spectrum of the physical mixture was compared with those of pure drug, lipid and surfactants 
and peak matching was done to detect any appearance or disappearance of peaks). 
 
Methodology (15) 
SNEDDS were formulated by spontaneous emulsification technique using slow 
aqueous titration 
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Construction of pseudo ternary phase diagrams (16, 17) 
Pseudo ternary phase diagrams were constructed to examine the formation of oil in 
water nanoemulsion with 4 components oil, surfactant, co surfactant, and aqueous phase. The 
4-component system consisted of (i) Capryol 90 and Capmul MCM 2:1 (Selected from 
solubility studies) (ii) surfactant Cremophore RH 40 with HLB value 12.5 (iii) a Co 
surfactant (Ethanol) and (iv)distilled water (aqueous phase). Surfactant and co surfactant 
mixture (SCoS) in each group were mixed in different volume ratios (1:0, 1:1, 1:2, 1:3, 2:1, 
3:1, 4:1). Seventeen combinations of oil and SCoS, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 
5:1, 4:1, 3:1, 2:1 were made so that maximum ratios were covered for the study to depict the 
boundaries of phases precisely formed in the phase diagrams Fig (1-2). Slow titration with 
aqueous phase (18) was done to each volume ratio of oil and SCoS and visual observation 
was carried out for transparency and flowability of the nanoemulsion.  
Different concentrations of oil from NE region of phase diagrams were selected, and 
the drug is incorporated. For each % of oil selected, the formula that used the minimum 
concentration of SCoS for its NE formulation was selected.  
 
Characterisation of nanoemulsion (19,20) 
The formulations were subjected to different thermodynamic stability studies (Table 
2) such as centrifugation, heating cooling cycle (21) and freeze thaw cycle, to avoid the 
selection of metastable formulations. Thermodynamic stability of nanoemulsion differentiates 
them from those systems which are kinetically stable and eventually phase separate. The 
dispersibility of the nanoemulsion was assessed using a standard USP XXII dissolution 
apparatus II.  The in vitro performance of the formulations was visually assessed by phase 
clarity, self emulsification time, and rate of emulsification. Rapidly forming (within 1min) 
nanoemulsion, having a clear or bluish appearance, rapidly forming, slightly less clear 
emulsion, having a bluish white appearance were selected for further studies (22) (Table 3). 
The selected formulations were prepared by dissolving 67 mg (single dose) of Fenofibrate 
and 5mg of Rosuvastatin in oil (10%, 15%, 20%, 25% etc.). Respective SCoS ratio was 
added to the oil, and mixed using vortex mixer. 
         The formulated SNEDDS were evaluated for the following parameters in vitro (table 3). 
SLNO PARAMETER METHOD 
1 Globule size & polydispersity index Zetasizer 3000 ( Malvern Instruments Worcestershire, UK) 
(fig 6) 
2 External Morphological Study Scanning Electron Microscopy(fig 7) 
3 Viscosity determination Brookfield DV-II ultra+ viscometer 
4 Electroconductivity study Electroconductometer (Conductivity meter 305, Systronic). 
5 
 
Refractive index and % 
transmittance 
Abbe refractometer & UV spectrophotometer. 
 
6 In vivo  performance 50,100, 1000 times dilution with various dissolution media 
viz: Water and Simulated gastric fluid (pH 1.2). 
7 Drug content UV Visible spectrophotometry. 
From the stock solution of Fenofibrate and Rosuvastatin, dilutions were prepared and 
the calibration curve in acetonitrile (ACN) constructed between concentration and peak area. 
 
Chromatographic conditions for simultaneous estimation of Fenofibrate and 
Rosuvastatin 
The following is the optimized chromatographic conditions were selected for the 
simultaneous estimation of Fenofibrate and Rosuvastatin (23). Shimadzu gradient HPLC 
system was used with following configurations: stainless steel column (Inertsil ODS, 250 x 
4.6mm, 5μ column), which was maintained at 25oC. The dual analytical were set, 248 nm for 
Rosuvastatin and 286 nm for Fenofibrate and samples of 5μl were injected to HPLC system. 
The mobile phase was a mixture of water (pH 2.5 adjusted with ortho-phosphoric acid) and 
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acetonitrile in ratio of 30:70 (v/v) at a flow rate of 1.0ml/min. The mobile phase was filtered 
through 0.45μm filter (Sartorius, Germany) and degassed for 10 minutes by sonication. 
 
In vitro drug release in simulated gastric fluid pH 1.2 
The quantitative in vitro release test (15) was performed in 250 ml pH 1.2 simulated 
gastric fluid using USP dissolution apparatus Type I at 50 rpm at 37±0.50c. The Optimized 
SNEDDS formulation containing single dose of Fenofibrate and Rosuvastatin were filled in 
Size 1cs of Hard gelatin capsule (24, 25) (CONISNAP). Samples were withdrawn at regular 
time intervals (0, 0.5, 1, 1.5, 2, hrs) and an aliquot amount of dissolution media was replaced. 
The release of drug from SNEDDS formulation was compared with the conventional tablet 
formulation and the samples were analyzed for the drug content (table 4). 
 
In vivo bioavailability studies (26) 
The experiments were carried out after getting the approval of the CPCSEA and 
IAEC, JSS College of Pharmacy, Ooty.Proposal no: 
JSSCP/IAEC/M.PHARM/PH.CEUTICS/01/2012-13 and their guidelines were followed 
throughout the experiment. 
 
Estimation of drug in rabbit plasma 
Healthy overnight fasted Male Sprague-Dawley rats weighing about 350-370gm were 
used for both in-vitro and in-vivo the experiments. The animals were given water ad.libitum 
during fasting and throughout the experiment. Zero hour fasting blood samples were 
withdrawn early in the morning. The animals were then divided into 2 groups each containing 
two animals. The dose for the rabbits was selected based on the surface area ratio of rabbit 
and man; and the dose was administered with an oral cannula. Group 1 received drug 
conventional marketed tablet formulation and group 2 received SNEDDS. Immediately after 
administration the animals were given 5ml of water. The animals were anaesthetized and the 
carotid artery is cannulated (27).  
Blood samples (0.5ml) were withdrawn from the carotid artery at 
0,0.25,0.5,0.75,1,2,4,6,8,12 hours with a sterile syringe. The blood samples were collected in 
a ria vial containing anti-coagulant (0.4 ml of 2.5% sodium citrate), centrifuged at 2500rpm 
for 4 min and the plasma samples were separated and stored at -200C. The plasma samples 
were deprotonated and extraction of drug was done by solid phase extraction (SPE) using 
ACN-water mixture and analyzed. Estimation of plasma samples by HPLC was carried out 
using optimized chromatographic conditions mentioned earlier (table 5). 
 
Pharmacokinetic data analysis 
Predicting the release behavior of the drug in vivo can be done by pharmacokinetic 
treatment of data. Pharmacokinetic parameters (table 6) after oral administration of 
Olanzapine in rabbits were calculated by Wagner-nelson method. The pharmacokinetic data 
was analyzed by one-way analysis of variance (ANOVA) using Tukey-Kramer method. 
 
In-vivo lymphatic absorption studies (28) 
 All the animals were suitably anesthetized, and cannulation of mesenteric lymph duct 
for collection of intestinal lymph and duodenum for the administration of rehydration 
solution was done as per the procedure (27). To study the lymphatic absorption, the lymph 
that drains from the intestinal lymphatic duct was collected at predetermined time intervals 
for 12 hrs, analyzed for drug concentration and multiplied with the volume of the lymph 
collected(fig 4). 
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Results and discussion 
Solubility studies of drug in different oils 
Solubility is an important criterion in formulation of SNEDDS, as the drug remains in 
the liquid form solubulized in the oil phase. Hence the oil phase in which the drug shows 
maximum solubility is to be selected for the purpose. From table 1 it was evident that 
Capryol 90 shows maximum solubility of Fenofibrate i.e 180 mg/mL and Capmul MCM 
shows maximum solubility of Rosuvastatin i.e 30 mg/mL. Hence the combination of Capryol 
90 and Capmul MCM in the ratio of 2:1 (which was calculated based upon the dose of the 
drugs) was selected for the formulation of SNEDDS.  
Table 1: Solubility studies 
OIL FENOFIBRATE 
SOLUBILITY(mg/mL) 
ROSUVASTATIN 
SOLUBILITY(mg/mL) 
CAPRYOL 90 270 30 
CAPMUL MCM 110 60 
LF 96 42 
IPM 72 21 
LG 84 24 
LL 126 44 
 
Pseudo ternary phase diagram study 
When surfactant alone (SCoS 1:0) was used only a small area of nanoemulsion is 
formed with oil solubulized upto 18% and SCoS 65%, while surfactant and co surfactant 
were taken in equal ratio (SCoS 1:1) there was a slight increase in nanoemulsion region but 
the oil solubulization increased upto 23% with 59% of SCoS. This could be due to the 
addition of co-surfactant which leads to greater penetration of oil phase into the surfactant 
thereby decreasing the interfacial tension. 
 
Fig 1: SCoS 1:1                                          Fig 2: SCoS 1:2 
When the concentration of co-surfactant is doubled (SCoS 1:2) nanoemulsion area 
increased considerably with 30% oil solubulized with 55% SCoS. There was no difference in 
nanoemulsion region and the oil solubulization remained same for (SCoS 1:3). But on further 
increase of co-surfactant (SCoS 1:4) the oil solubulization decreased to 28%. 
When Surfactant concentration (SCoS 2:1) was doubled nanoemulsion area was large 
and the maximum oil solubulization was up to 32% with only 52% of SCoS. A further 
increase in surfactant concentration i.e., SCoS 3:1 resulted in decrease of oil solubulization of 
only up to 25%. For SCoS 4:1 even a high concentration of SCoS 65% resulted in less 
nanoemulsion area with only 19% of oil solubulization. 
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Thermodynamic stability studies and dispersibility tests 
The selected formulations from the pseudo ternary phase diagrams were subjected to 
different thermodynamic stability studies and the formulations which survived 
thermodynamic stability studies were taken for dispersibility test. (Table no: 2). 
Thermodynamic stability studies differentiate those nanoemulsion formulations from those of 
kinetically stable and undergo phase separation. This implies that the formulations contain 
adequate amounts of SCoS concentration required for nanoemulsion formulation, which 
decreases the energy required for nanoemulsion formation. This decreased energy contributes 
to the stability of nanoemulsion. The nanoemulsion formulation on entering the GI tract 
undergoes infinite dilution leading to phase separation of the formulation due to poor aqueous 
solubility of the drug.Formulations which passed the dispersibility studies were certain to 
remain as nanoemulsion upon dispersion in the aqueous environment of the GIT. For oral 
nanoemulsion the process of dilution by the GI fluids will result in the gradual desorption of 
the surfactant located at the globule interface. The process is thermodynamically driven by 
the requirement of the surfactant to maintain an aqueous phase concentration equivalent to its 
critical micelle concentration. 
Table no: 2 Thermodynamic stability studies and dispersibility test. 
*** Formulation which passed the dispersibility test; P- pass; F- fail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulations which passed thermodynamic stability tests and dispersibility test were 
subjected to globule size analysis, refractive index determination, viscosity determination and 
in vitro release studies. 
 
 
SCoS Oil % SCoS % Aq % Centrifugation H/C cycle Freeze 
Thaw 
Dispersion 
1:0 10 
15 
30 
56 
60 
29 
F 
P 
P 
F 
P 
F 
- 
- 
1:1 10 
15 
20 
25 
18 
25 
36 
45 
72 
60 
54 
30 
P 
P 
P 
P 
P 
P 
P 
P 
P 
P 
P 
P 
- 
*** 
- 
*** 
1:2 10 
15 
20 
25 
30 
27 
33 
37 
44 
54 
63 
52 
43 
31 
16 
P 
P 
P 
P 
P 
F 
P 
P 
P 
P 
P 
P 
F 
P 
P 
- 
*** 
- 
- 
*** 
1:3 10 
15 
20 
25 
30 
18 
19 
30 
36 
51 
72 
66 
50 
39 
19 
P 
P 
P 
P 
F 
F 
P 
P 
P 
P 
F 
P 
P 
F 
P 
- 
- 
- 
- 
- 
1:4 10 
15 
20 
18 
21 
35 
72 
64 
45 
P 
P 
P 
P 
P 
P 
P 
P 
P 
- 
- 
- 
2:1 10 
15 
20 
25 
30 
22 
25 
33 
40 
45 
68 
60 
47 
35 
15 
F 
P 
P 
F 
P 
P 
P 
F 
P 
P 
F 
P 
P 
P 
P 
- 
- 
- 
- 
- 
3:1 10 
15 
20 
18 
25 
32 
72 
60 
48 
P 
F 
P 
P 
P 
P 
P 
P 
F 
- 
- 
- 
4:1 10 
15 
20 
25 
70 
60 
F 
P 
P 
F 
P 
P 
- 
- 
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Characterization studies 
Optimized formulations selected from phase diagram at a difference of 5% w/w of oil 
having least SCoS concentration that passed dispersibility test were selected, named as 
formulation A,B,C, and D. They were subjected to in vitro characterization studies (Table 4). 
The globule size increases with increase in concentration of oil in formulation and 
decreases with increase in the concentration of SCoS. The mean globule size of the 
formulation A containing 25% oil was 90 nm while as formulation, B containing 30% oil was 
254.3nm and formulation D with 15% oil was 40 nm. Since the globule size of the droplets 
was much smaller than that of the blood capillaries (400nm), there are minimal chances of 
capillary blockage during transport of the droplets. Thus higher circulation time of the 
droplets after in vivo application is also favored. The polydispersity index (PDI) of 
formulation A and C was 0.287 and 0.398 suggesting uniformity in the globule size of the 
formulation but in the case of formulation B and D the PDI was 0.723 and 0.910 so these 
formulations were dropped from further studies.  
Zeta potential of a formulation relates to its colloidal stability. It indicates the degree 
of repulsion between adjacent and similarly charged particles in the dispersion. For molecules 
that are small enough a high zeta potential confers stability and resists aggregation. The zeta 
potential of the formulations A and C were -19.0 and -22, indicates that the formulations are 
stable. 
The viscosity of the optimized formulations was determined. It was observed that 
viscosity of all the formulations is less than 31 cp. Formulation A and C has the minimum 
viscosity 22.3cp and 19.2cP, while B has highest viscosity of 30.1cp perhaps because of its 
higher oil content. Lower viscosity is an ideal characteristic of the o/w nanoemulsion. 
Conductivity of the optimized formulations was found in range of 451-522.3 μS/cm. 
From the viscosity and the electro-conductivity study it is concluded that the system is of o/w 
type. 
The refractive index of the developed system was similar to the refractive index of the 
water (1.333). In addition, the developed system showed percent transmittance > 97%. The 
observed transparency of the system is due to the fact that the maximum size of the droplets 
of the dispersed phase is not larger than 1/4 th of the wavelength of visible light. Thus, NE 
scatters little light and was therefore transparent or translucent. 
Fenofibrate and Rosuvastatin from the SNEDDS were extracted by dissolving in 
ACN, analyzed spectrophotometrically against solvent blank. Drug content of the optimized 
formulations were found to be 70mg, 5mg; 120mg, 8.5mg; 70mg, 5mg; 140mg,10mg for 
formulations A, B, C, D respectively. 
Table 3: Characterization of Nanoemulsion 
Formulation A B C D 
SCoS(ml) 1:1 1:1 1:2 1:2 
Oil % 15 25 15 30 
S% 12.5 22.5 11 18 
Cos% 12.5 22.5 22 36 
Aq% 60 30 52 16 
Globule size(nm) 90 254.3 212 40 
PDI 0.287 0.723 0.398 0.910 
Zeta Potential(mV) -19.0 -17 -22 -5 
Viscosity(cP) 22.3 30.1 19.2 - 
Conductivity(μS/cm) 451.3 - 522.3 - 
Refractive Index 1.49 - 1.27 - 
%Transmittance 99.43 - 98.9 - 
Drug content(mg/mL) 
Fenofibrate  
Rosuvastatin  
 
70 
 
120 
 
70 
 
140 
5 8.5 5 10 
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From the above analysis the formulation A was selected for drug incorporation and in 
vitro and in vivo studies. 
 
Scanning electron microscopy (SEM) 
The scanning electron microscopic study reveals the external morphology of the 
nanoparticles and from fig 3 it was evident that maximum nanoparticles were nearly spherical 
in shape.  
Fig 3: Scanning Electron Microscopic picture of Nanoemulsion 
 
 
In vitro drug release 
In vitro dissolution studies were performed in pH 1.2 simulated gastric media. 
Comparative dissolution studies were performed to investigate the drug dissolution from 
SNEDDS and marketed tablet formulation containing same quantity of drug. In vitro 
dissolution studies showed that Fenofibrate is rapidly released ≥98 % and ≥96% of 
Rosuvastatin from the optimized SNEDDS. Initially during the first 15 min, the SNEDDS 
had shown a release of ≥38% of Fenofibrate and ≥33% of Rosuvastatin, but by the end of 
30min, there was a drastic change in the release behavior which was upto ≥64% of 
Fenofibrate and ≥56% of Rosuvastatin. Out of this ≥80% of the drug released during first 
hour of the study. In contrast, the marketed formulation has shown a release of ≥ 60%. This is 
because of the small globule size, and eventually higher surface area in case of SNEDDS, 
which permits faster rate of drug release. Being droplets and the drug in solution form, instant 
absorption should have been taken place. Since the carrier is lipid, it undergoes lipolysis in 
the presence of bile salts and pancreatic lipases etc.  Therefore the surfactant layer around the 
droplets gets released and is converted to micelles, reverse micelles etc.  Sometimes this may 
lead to precipitation of drug since the drug gets detached from the droplets. This is the case 
where the surfactants are directly involved in the solubility of the drug. Infact the total 
amount of drug release is delayed due to this lipolysis process.  
Table no: 4 In vitro dissolution data in pH 1.2 simulated gastric fluids. 
Time 
(min) 
% Cumulative release 
SNEDDS Marketed formulation 
Fenofibrate Rosuvastatin Fenofibrate Rosuvastatin 
15 38.21 33.17 32.33 29.9 1 
30 64.61 56.28 49.49 45.18 
45 75.37 63.41 56.32 52.42 
60 80.37 81.37 60.36 59.36 
90 95.37 93.23 64.00 62.10 
120 98.95 96.64 68.30 64.20 
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In vivo bioavailability studies 
In vivo bioavailability studies were performed to quantify SNEDDS formulation after 
oral administration and to compare the bioavailability of SNEDDS with that marketed 
formulation. From the table 5 it can be inferred that the SNEDDS formulation showed 
maximum plasma concentration of 80% by the end of first hour while the pure drug 
suspension and marketed formulations showed only 54 and 57% release by that time 
respectively. The pure drug suspension and marketed formulations took 2hours to reach 
maximum plasma concentration of 56 and 61% respectively. From the above analysis it is 
evident that the SNEDDS formulation showed improved rate of drug release compared to the 
conventional marketed formulations. The SNEDDS showed maximum drug concentration in 
half of the time taken by the pure drug suspension and the marketed formulation. 
Table no: 5 Comparative in vivo bioavailability studies  
Time 
(hrs) 
Marketed Formulation (ng/h/ml) SNEDDS (%) 
Fenofibrate  Rosuvastatin  Fenofibrate  Rosuvastatin  
0.25 21.44 ± 1.25 1.55±0.98 32.16±1.80** 2.05±0.92** 
0.5 24.79 ± 1.71 1.79±0.52 48.64± 2.41*** 3.23±0.16** 
0.75 28.81 ± 1.90 2.13±0.85 53.6±2.76*** 3.7±0.02*** 
1 32.83 ±1.92 2.31±0.64 56.54±2.14** 4.16±0.56*** 
2 35.175 ± 1.13 2.38±0.09 54.002±2.18** 3.96±0.80** 
4 32.75 ± 1.74 2.21±0.62 48.48±1.79** 3.51±0.62** 
6 26.66 ±1.79 1.85±0.33 42.96 ±1.74** 2.91±0.32** 
8 24.12 ±1.51 1.70±0.02 37.25±1.58** 2.03±0.43** 
12 21.44 ±1.64 1.45±0.56 22.38±1.19** 1.51±0.72** 
Values are expressed as mean ±S.D; n=3 
*P<0.05; **P< 0.01;***P<0.001 when compared with marketed formulation. 
 
 One way ANOVA followed by TUKEY-KRAMERS multiple comparison tests. 
 
Pharmacokinetic treatment 
Pharmacokinetic parameters were calculated from the in vivo release of Fenofibrate 
and Rosuvastatin in Sprague-Dawley rats for SNEDDS, and marketed tablet using Wagner-
Nelson method (table 6). 
Since the rate limiting step in the absorption of Fenofibrate and Rosuvastatin was 
dissolution from the formulation and the results from the study reveals that the dispersion of 
the drug (since the drug is completely dissolved in the oil phase) into the aqueous 
gastrointestinal environment is the rate limiting step in case of SNEDDS and plays a major 
role for absorption. It can be explained that, following oral administration, SNEDDS disperse 
spontaneously to form a nanoemulsion in the GI fluid where the active components are 
present in a solubulized form, and the small droplet size provides a large surface area for drug 
absorption. Such an ultra fine dispersion of the oil will afford rapid and extensive absorption. 
In addition high concentration of surfactant in SNEDDS may increase permeability of the oil 
across the cell membrane, and lymphatic transport through the transcellular pathway. As the 
lipolysis proceeds amount of drug available for absorption is also more. This could be the 
reason for the formulation to take around 1hr to achieve Tmax. Whereas the conventional 
marketed formulation did not result in the same manner. Fact may be that since it takes more 
time for disintegration and to go into the solution. Hence it took more than 2hrs to achieve 
Tmax, and moreover the extent of absorption which is evident from AUC0-t and AUC0-∞, the 
SNEDDS achieved maximum which is statistically significant.  
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Table 6: Pharmacokinetic parameters 
Pharmacokinetic  
parameters 
Marketed formulation SNEDDS 
Fenofibrate Rosuvastatin Fenofibrate Rosuvastatin 
T max(h) 2 2 1 1 
Ke 0.283±0.0153 0.245±0.0124 0.7343±0.0162** 0.944±0.0132** 
C max(ng/ml) 35.175±1.13 2.38±1.64 56.548±2.14** 4.16±2.56** 
AUC0-t(ng h/ml) 326.1013±22.56 22.50125±2.48 489.305±98.9* 32.735±8.28* 
AUC0-∞(ng.h/ml) 401.86±21.6 28.4196±23.8 519.78±59.35* 34.335±55.45* 
Fr ----- ----- 1.69 1.64 
Values are expressed as mean ±S.D; n=3 
*P<0.05; **P< 0.01;***P<0.001 when compared with marketed formulation. 
 
 One way ANOVA followed by TUKEY-KRAMERS multiple comparison tests. 
 The relative bioavailability of the SNEDDS was 1.69 and 1.64 for Fenofibrate and 
Rosuvastatin which is 0.69 and 0.64 folds increase when compared to marketed formulation. 
From the above discussion it was evident that SNEDDS showed improved bioavailability and 
drug disposition compared to the marketed formulation.  This results shows the lymphatic 
absorption plays a major role in enhanced bioavailability of lipid formulations i.e SNEDDS. 
 
In vivo lymphatic absorption studies 
In vivo lymphatic absorption studies in Sprague-Dawley rats were performed and the 
intestinal lymphatic fluid was collected for a period of 12hrs. The amount of drug that has 
been absorbed through lymphatic system was found to reach a maximum of 41% by 2 hr after 
administration of drug while the . From then the rate at which drug absorbed via lymphatic 
route showed a decline. This is due to the lipid nature of the droplets, micelles and reverse 
micelles formed during lipolysis. It is also evident that the result of lipolysis did not account 
for precipitation. Hence maximum amount of drug was available for absorption. Moreover 
the lipid carriers and the surfactants might have involved in overcoming the P-gp efflux, 
thereby increasing the drug available for absorption which is evident from the lymphatic drug 
absorption study.  
Fig: 4 In-vivo Lymphatic Absorption 
 
Conclusion 
 By formulating Fenofibrate and Rosuvastatin as the SNEDDS (with appropriate 
selection of oil (2:1) and SCoS(1:1))  in combination, the problems faced by the conventional 
formulations could be overcome. Since being a lipid formulation enhanced bioavailability by 
lymphatic system mediated drug absorption is possible.   
 
European Scientific Journal   December 2013 /SPECIAL/ edition vol.4  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
 616 
References: 
Tang B, Chang G, Gu J.C, Xu C-H. Development of solid self-nanoemulsifying drug delivery 
systems: Preparation techniques and dosage forms. Drug Discovery Today 2008 
doi:10.1016/j.drudis. 
Yohei Kawabata, Koichi Wada, Manabu Nakatani, Shizuo Yamada, Satomi Onoue (2011) 
Formulation design for poorly water-soluble drugs based on biopharmaceutics classification 
system: Basic approaches and practical applications; International Journal of Pharmaceutics 
420:1– 10. 
Abdalla A, Klein S, Mader K. A new self-emulsifying drug delivery system (SEDDS) for 
poorly soluble drugs: Characterization, Dissolution, in-vitro digestion and incorporation into 
solid pellets. European Journal of Pharmaceutical Sciences. 2008; 35: 457-64. 
Colin W. Pouton, Christopher J.H. Porter. Formulation of lipid-based delivery systems for 
oral administration: Materials, methods and strategies; Advanced Drug Delivery Reviews 
2008; 60: 625–637. 
Li X, Wang L, Dong J, Chen J, Eastoe J. Design and optimization of a new self-
nanoemulsifying drug delivery system. Journal of Colloid and Interface Science. 2009; 330: 
443-8 
Anne.T.Larsen, Philip Sassene, Anette Mullertz  (2011)  In vito lipolysis model as a tool for 
the characterization of oral lipid and surfactant based drug delivery systems. International 
journal of pharmaceutics 417: 245-255 
Emad B. Basalious, Nevine Shawky, Shaimaa M. Badr-Eldin(2010) SNEDDS containing 
bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: 
Development and optimization; International Journal of Pharmaceutics 391: 203–211. 
Gao D, Delmare D, Narang AS. Stable drug encapsulation in micelles and microemulsions. 
International journal of Pharmaceutics. 2007; 345:9-25.  
Shaji J, Joshi V, Self-microemulsifying drug delivery system (SMEDDS) for improving 
bioavailability of hydrophobic drugs and its potential to givesustained release dosage forms. 
Indian J. Pharm. Educ.2005;39(3):130-5. 
www.drugs.com 
Shek A, Ferrill.MJ. Statin-Fibrate Combination Therapy; Ann Pharmacother. 2001 Jul-
Aug;35(7-8):908-17.  
Arik Dahan, Avivit Mendelman, Sofia Amsili, Nathan Ezov, Amnon Hoffman. The effect of 
general anesthesia on the intestinal lymphatic transport of lipophilic drugs: Comparison 
between anesthetized and freely moving conscious rat models; European Journal Of 
Pharmaceutical Sciences 32 (2007) 367–374. 
Sheikh Shafiq-un-Nabi, Faiyaz Shakeel, Sushma Talegaonkar, Javed Ali, Sanjula Baboota, 
Alka Ahuja,Roop K. Khar,and Mushir Ali(2007) Formulation Development and Optimization 
Using Nanoemulsion Technique:A Technical Note. AAPS PharmSciTech 8 (2) Article 28 
Elnaggar YSR, El-Massik MA, Abdallah OA. Self-nanoemulsifying drug delivery systems of 
tamoxifen citrate: Design and optimization. International Journal of Pharmaceutics. 2009; 
380: 133–41.  
K. Bouchemal, S. Briançon, E. Perrier, H. Fessi(2004) Nano-emulsion formulation using 
spontaneous emulsification: solvent, oil and surfactant optimisation, International Journal of 
Pharmaceutics 280: 241–251. 
Raman Suresh Kumar, Urmila Sri Syamala, Punukollu Revathi, Sumanth Devaki, Pathuri 
Raghuveer and Kuppuswamy Gowthamarajan. Self Nanoemulsifying Drug Delivery System 
of Olanzapine for Enhanced Oral Bioavailability: In-vitro, In-vivo Characterization and In 
vitro -In vivo Correlation; J Bioequiv Bioavailab 5: 201- 208. 
European Scientific Journal   December 2013 /SPECIAL/ edition vol.4  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
 617 
Ghosh PK, Majithiya RJ, Umrethia ML, Murthy RS. Design and Development of 
Microemulsion Drug Delivery System of Acyclovir for Improvement of Oral Bioavailability. 
AAPS PharmSciTech. 2006; 7 (3): Article 77.  
Kunal Jain, R.Suresh Kumar, Sumeet Sood, K. Gowthamarajan. Enhanced Oral 
Bioavailability of Atorvastatin via Oil-in-Water Nanoemulsion using Aqueous Titration 
Method; J. Pharm. Sci. & Res. Vol.5 (1), 2013, 18 – 25. 
Sheikh Shafiq, Faiyaz Shakeel, Sushma Talegaonkar, Farhan J. Ahmad,Roop K. Khar, 
Mushir Ali(2007) Development and bioavailability assessment of ramipril nanoemulsion 
formulation. European Journal of Pharmaceutics and Biopharmaceutics 66: 227–243. 
Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an 
approach to enhance oral bioavailability. Drug Discovery Today. 2010.  
Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel 
nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids and Surfaces 
B: Biointerfaces. 2010; 76: 410–20. 
Charman WN, Khoo SM, Humberstone AJ, Porter C J.H. Formulation design and 
bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. 
International Journal of Pharmaceutics.1998; 167: 155–164. 
Suresh Kumar GV, Rajendraprasad Y. Development and Validation of Reversed-Phase 
HPLC Method for Simultaneous Estimation of Rosuvastatin and Fenofibrate in Tablet 
Dosage Form; International Journal of PharmTech Research, Vol.2, No.3, July-Sept 2010. 
U.S. Department of Health and Human Services, FDA, Dissolution methods, 2004. 
Nagarsenker MS, Date AA. Design and evaluation of self-nanoemulsifying drug delivery 
systems (SNEDDS) for cefodoxime proxetil. International Journal of Pharmaceutics. 2007; 
329: 166–72.  
Vibeke Hougaard Sunesen, Betty Lomstein Pedersen,Henning Gjelstrup Kristensen, Anette 
M¨ullertz(2005) In vivo in vitro correlations for a poorly soluble drug, danazol, using the 
flow-through dissolution method with biorelevant dissolution media. European Journal of 
Pharmaceutical Sciences 24: 305–313. 
Glenn A. Edwards, Christopher J.H. Porter, Suzanne M. Caliph, Shui-Mei Khoo, W.N. 
Charmanb. Animal models for the study of intestinal lymphatic drug transport; Advanced 
Drug Delivery Reviews 50 (2001) 45–60. 
Michael Boyd, Verica Risovic, Philip Jull, Eugene Choo, Kishor M. Wasan. A stepwise 
surgical procedure to investigate the lymphatic transport of lipid-based oral drug 
formulations: Cannulation of the mesenteric and thoracic lymph ducts within the rat; Journal 
of Pharmacological and Toxicological Methods 49 (2004) 115– 120. 
 
 
 
 
 
 
 
 
 
